What differences have been observed in provision of clinical care between men and women with CAD?
From various studies, it has been observed that the frequency of risk-modifying therapies such as statins, aspirin, and beta blockers being prescribed to women with CAD after episodes of ACS is significantly lower than among men. Moreover, the outcomes of revascularization appear to be less favorable among women than men, although very few women were enrolled in COURAGE. In various risk models, the odds of in-hospital death after PCI have ranged from 25% to 80% higher for women than for men. The risk of procedural complications also appears to be significantly higher in women. Finally, in the New York State registry, the odds of in-hospital death for women were 2-fold higher than for men.